 |
|
|
| |
Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals
|
| |
| |
EASL 2022 June 22-26 London
J. TURNES1, A. GARCÍA-HEROLA2, R. MORILLO-VERDUGO3, M. MÉNDEZ4, C. DE ALVARO4, C. HERNÁNDEZ5, and A. SICRAS MAINAR6
1. Gastroenterology and Hepatology Department, CHU. Pontevedra, Spain, 2. Digestive Medicine Department. Hospital Marina Baixa de Villajoyosa (Alicante), Spain, 3. Hospital Pharmacy, Hospital de Valme, AGS Sur de Sevilla, Spain, 4. Medical Affairs, Gilead Sciences S.L., Madrid, Spain, 5. Global Medical Affairs, Gilead Sciences Europe Ltd, U.K, 6. Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain.
|
| |
|
|
|
|
|
